About five years ago, I ran into a problem many people face as they get older: The people I holiday shop for typically just buy everything they want throughout the year. That, of course, left me ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Reverse: 1999 is a gacha game. Players will pull from active Banners that offer a selection of featured characters ranging in rarity. The rarity of these characters is typically tethered to their ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Angelica Leicht is a seasoned personal finance writer and editor with nearly two decades of experience but just one goal: to help readers make the best decisions for their wallets. Her expertise spans ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

January 2, 2026: Happy New Year! We added two new Reverse 1999 codes which provide Clear Drops and more. What are the new Reverse 1999 codes? If you're making a start in Bluepoch's strategic RPG, ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...